News releases
Date
Language

Type of release


News Release date Type of release Download
 
Federal Circuit Court afsiger dom i patentsag om Prandin® (repaglinid) Jun 18, 2013 Company announcement DK
Federal Circuit Court rules on patent litigation involving Prandin® (repaglinide) Jun 18, 2013 Company announcement UK
Share repurchase programme Jun 17, 2013 Company announcement UK
Sikkerhedsprofilen for Victoza® yderligere styrket på videnskabeligt møde i USA om pankreatitis, diabetes og bugspytkirtelkræft Jun 13, 2013 Press release DK
Victoza® safety profile further supported at scientific workshop on pancreatitis, diabetes and pancreatic cancer Jun 13, 2013 Press release UK
Share repurchase programme Jun 10, 2013 Company announcement UK
Aktietilbagekøbsprogram Jun 10, 2013 Company announcement DK
Novo Nordisk afviser anklager om skattefusk i DR1 Søndag Jun 10, 2013 Press release DK
Novo Nordisk A/S: Share repurchase programme Jun 03, 2013 Company announcement UK
Novo Nordisk A/S : aktietilbagekøbsprogram Jun 03, 2013 Company announcement DK
Novo Nordisk indsender registreringsansøgning for IDegLira i EU til behandling af type 2-diabetes May 31, 2013 Company announcement DK
Novo Nordisk files for regulatory approval of IDegLira in the EU for the treatment of type 2 diabetes May 31, 2013 Company announcement UK
Novo Nordisk supports new global commitment to fight noncommunicable diseases May 30, 2013 Featured story UK
Novo Nordisk and the Ministry of Health in Malaysia join forces to improve pre-pregnancy health May 28, 2013 Featured story UK
Aktietilbagekøbsprogram May 27, 2013 Company announcement DK
Share repurchase programme May 27, 2013 Company announcement UK
Novo Nordisk reports 8% weight loss in phase 3a obesity trial with liraglutide 3 mg May 23, 2013 Company announcement UK
Novo Nordisk rapporterer 8% vægttab i fase 3a-fedmestudie med liraglutid 3 mg May 23, 2013 Company announcement DK
Share repurchase programme May 21, 2013 Company announcement UK
Aktietilbagekøbsprogram May 21, 2013 Company announcement DK
Novo Nordisk rapporterer positive resultater fra det første fase 3-studie med langtidsvirkende faktor IX til behandling af hæmofili B May 17, 2013 Company announcement DK
Novo Nordisk reports positive results from first phase 3 trial with long-acting factor IX for treatment of haemophilia B May 17, 2013 Company announcement UK
Share repurchase programme May 13, 2013 Company announcement UK
Aktietilbagekøbsprogram May 13, 2013 Company announcement DK
Novo Nordisk invests DKK 380 million in its Kalundborg plant May 06, 2013 Press release UK
Novo Nordisk investerer 380 millioner kroner i Kalundborg May 06, 2013 Press release DK
Aktietilbagekøbsprogram May 03, 2013 Company announcement DK
Share repurchase programme May 03, 2013 Company announcement UK
Novo Nordisk A/S køber B-aktier til en værdi af 2,5 mia. kr. fra Novo A/S som led i det løbende aktietilbagekøbsprogram May 03, 2013 Company announcement DK
Novo Nordisk A/S purchases B shares worth DKK 2.5 billion from Novo A/S as part of the on-going share repurchase programme May 03, 2013 Company announcement UK
Trading in Novo Nordisk shares by board members, executives and associated persons on 1 May 2013 May 02, 2013 Company announcement UK
Bestyrelsesmedlemmers, koncerndirektørers og nærtstående personers handel med Novo Nordisk-aktier den 1. maj 2013 May 02, 2013 Company announcement DK
Resultat af primær drift steg med 18% i første kvartal af 2013 May 01, 2013 Company announcement DK
Increased operating profit by 18% in the first quarter of 2013 May 01, 2013 Company announcement UK
Novo Nordisk A/S : det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 30. april 2013 Apr 30, 2013 Company announcement DK
Novo Nordisk A/S : Total number of voting rights and share capital in Novo Nordisk A/S as of 30 April 2013 Apr 30, 2013 Company announcement UK
Share repurchase programme Apr 30, 2013 Company announcement UK
Aktietilbagekøbsprogram Apr 30, 2013 Company announcement DK
10,000 children’s lives improved through new clinics Apr 25, 2013 Featured story UK
Aktietilbagekøbsprogram Apr 22, 2013 Company announcement DK
Share repurchase programme Apr 22, 2013 Company announcement UK
Nedsættelse af aktiekapitalen Apr 22, 2013 Company announcement DK
Reduction of the share capital Apr 22, 2013 Company announcement UK
Aktietilbagekøbsprogram Apr 15, 2013 Company announcement DK
Share repurchase programme Apr 15, 2013 Company announcement UK
Apr 09, 2013 Featured story DK
Diabetes on the agenda in Mexico Apr 09, 2013 Featured story UK
Aktietilbagekøbsprogram Apr 08, 2013 Company announcement DK
Share repurchase programme Apr 08, 2013 Company announcement UK
Status regarding Novo Nordisk's holding of its own shares (31 March 2013) Apr 02, 2013 Company announcement UK
Status vedrørende Novo Nordisks beholdning af egne aktier (31. marts 2013) Apr 02, 2013 Company announcement DK
Novo Nordisk A/S - aktietilbagekøbsprogram Apr 02, 2013 Company announcement DK
Novo Nordisk A/S - Share repurchase programme Apr 02, 2013 Company announcement UK
Aktietilbagekøbsprogram Mar 25, 2013 Company announcement DK
Share repurchase programme Mar 25, 2013 Company announcement UK
Den langsigtede aktiebaserede incitamentsordning for Senior Management Board for 2013 Mar 21, 2013 Company announcement DK
2013 long-term, share based incentive programme for the Senior Management Board Mar 21, 2013 Company announcement UK
Beslutninger på den ordinære generalforsamling i Novo Nordisk A/S Mar 20, 2013 Company announcement DK
Resolutions from the Annual General Meeting of Novo Nordisk A/S Mar 20, 2013 Company announcement UK
6,900 applications for 48 graduate positions Mar 19, 2013 Featured story UK
Mar 19, 2013 Featured story DK
Share repurchase programme Mar 18, 2013 Company announcement UK
Aktietilbagekøbsprogram Mar 18, 2013 Company announcement DK
People with type 2 diabetes achieve 6% weight loss with liraglutide 3 mg in phase 3a obesity trial Mar 18, 2013 Company announcement UK
Type 2-diabetikere opnår 6% vægttab med liraglutid 3 mg i fase 3a-fedmestudie Mar 18, 2013 Company announcement DK
Novo Nordisk A/S : aktietilbagekøbsprogram Mar 11, 2013 Company announcement DK
Novo Nordisk A/S : share repurchase programme Mar 11, 2013 Company announcement UK
In Nigeria, a new project prompts easier insulin access Mar 05, 2013 Featured story UK
Novo Nordisk A/S - Share repurchase programme Mar 04, 2013 Company announcement UK
Novo Nordisk A/S - aktietilbagekøbsprogram Mar 04, 2013 Company announcement DK
Aktietilbagekøbsprogram Feb 25, 2013 Company announcement DK
Share repurchase programme Feb 25, 2013 Company announcement UK
Notice for the Annual General Meeting of Novo Nordisk A/S Feb 22, 2013 Company announcement UK
Indkaldelse til ordinær generalforsamling i Novo Nordisk A/S Feb 22, 2013 Company announcement DK
Novo Nordisk A/S : Share repurchase programme Feb 18, 2013 Company announcement UK
Novo Nordisk A/S : aktietilbagekøbsprogram Feb 18, 2013 Company announcement DK
Novo Nordisk lancerer NovoSeven® med engangssprøjte til hurtig standsning af blødninger Feb 14, 2013 Press release DK
Novo Nordisk launches NovoSeven® with pre-filled syringe for fast bleeding control Feb 14, 2013 Press release UK
Aktietilbagekøbsprogram Feb 11, 2013 Company announcement DK
Share repurchase programme Feb 11, 2013 Company announcement UK
Bestyrelsesmedlemmers, koncerndirektørers og nærtstående personers handel med Novo Nordisk-aktier den 8. februar 2013. Feb 11, 2013 Company announcement DK
Trading in Novo Nordisk shares by board members, executives and associated persons on 8 February 2013 Feb 11, 2013 Company announcement UK
Novo Nordisk receives Complete Response Letter in the US for Tresiba® and Ryzodeg® Feb 10, 2013 Company announcement UK
Novo Nordisk modtager Complete Response Letter i USA vedrørende Tresiba® og Ryzodeg® Feb 10, 2013 Company announcement DK
Press release: Novo Nordisk files annual report with the SEC Feb 07, 2013 Company announcement UK
Novo Nordisk-kommentar vedr. skattebetaling i Danmark Feb 05, 2013 Press release DK
Feb 05, 2013 Press release UK
Det tidligere omtalte Warning Letter fra FDA publiceret Feb 05, 2013 Company announcement DK
Previously announced FDA Warning Letter published Feb 05, 2013 Company announcement UK
Novo Nordisk har publiceret sin årsrapport for 2012 Feb 04, 2013 Press release DK
Novo Nordisk publishes its 2012 Annual Report Feb 04, 2013 Press release UK
Trading in Novo Nordisk shares by board members, executives and associated persons on 31 January 2013 Feb 01, 2013 Company announcement UK
Bestyrelsesmedlemmers, koncerndirektørers og nærtstående personers handel med Novo Nordisk-aktier den 31. januar 2013 Feb 01, 2013 Company announcement DK
Novo Nordisks resultat af primær drift steg med 32% i 2012 Jan 31, 2013 Company announcement DK
Novo Nordisk increased operating profit by 32% in 2012 Jan 31, 2013 Company announcement UK
Novo Nordisk A/S - aktietilbagekøbsprogram Jan 30, 2013 Company announcement DK
Novo Nordisk A/S - Share repurchase programme Jan 30, 2013 Company announcement UK
Tresiba® (insulin degludec) og Ryzodeg® (insulin degludec/insulin aspart) får markedsføringstilladelse i Europa Jan 21, 2013 Company announcement DK
Tresiba® and Ryzodeg® receive marketing authorisations in Europe Jan 21, 2013 Company announcement UK
Share repurchase programme Jan 21, 2013 Company announcement UK
Aktietilbagekøbsprogram Jan 21, 2013 Company announcement DK
Aktietilbagekøbsprogram Jan 14, 2013 Company announcement DK
Share repurchase programme Jan 14, 2013 Company announcement UK
Novo Nordisk A/S - Share repurchase programme Jan 07, 2013 Company announcement UK
Aktietilbagekøbsprogram Jan 07, 2013 Company announcement DK
Novo Nordisk A/S: Status regarding Novo Nordisk's holding of its own shares (31 December 2012) Jan 02, 2013 Company announcement UK
Novo Nordisk A/S: Status vedrørende Novo Nordisks beholdning af egne aktier (31. december 2012) Jan 02, 2013 Company announcement DK
Novo Nordisk A/S - aktietilbagekøbsprogram Jan 02, 2013 Company announcement DK
Novo Nordisk A/S - Share repurchase programme Jan 02, 2013 Company announcement UK
Ryzodeg® (insulin degludec/insulin aspart) approved in Japan Dec 25, 2012 Company announcement UK
Ryzodeg® (insulin degludec/insulin aspart) godkendt i Japan Dec 25, 2012 Company announcement DK
Det sidste fase 3a-studie for IDegLira afsluttet, og FIAsp godkendt til fase 3-udvikling Dec 19, 2012 Company announcement DK
The final phase 3a trial for IDegLira completed, and FIAsp approved for phase 3 development Dec 19, 2012 Company announcement UK
Enter search word